<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02494804</url>
  </required_header>
  <id_info>
    <org_study_id>GLICIK001</org_study_id>
    <nct_id>NCT02494804</nct_id>
  </id_info>
  <brief_title>Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas</brief_title>
  <official_title>A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Stage I-II Malignant Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First People's Hospital of Changzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First People's Hospital of Changzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether combining of Temozolomide and
      cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with
      Malignant Gliomas. The effectiveness and safety of CIK cells for the treatment of Malignant
      Glioma is also evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2030</completion_date>
  <primary_completion_date type="Anticipated">July 2028</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cytokine-Induced Killer Cells</condition>
  <condition>Milignant Gliomas</condition>
  <arm_group>
    <arm_group_label>Temozolomide</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Temozolomide+CIK</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Autologous cytokine-induced killer cells were transfer via venous one week after Temozolomide treat</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days</description>
    <arm_group_label>Temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CIK</intervention_name>
    <description>The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat</description>
    <arm_group_label>Temozolomide+CIK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Histologically confirmed intracranial Grade 1 or 2 anaplastic glioma or glioblastoma
        (astrocytic tumor, anaplastic oligodendroglioma, or oligoastrocytoma).

        Received prior standard radiation for a Grade 3 or 4 astrocytic tumor with a minimum
        cumulative dose of 40 Gy administered.

        Completed at least one full cycle of temozolomide of 200 mg/m2/day administered on Days 1-5
        of a 28-day cycle, without unacceptable toxicity or progression.

        Karnofsky performance status of 60 or more. Adequate organ and bone marrow function as
        defined by hematological and serum chemistry limits.

        At least 18 years old. Both men and women must practice adequate contraception. Informed
        consent.

        Exclusion Criteria:

        Progressed while on temozolomide. Evidence of acute intracranial or intratumoral hemorrhage
        &gt; Grade 1. Not recovered from the toxic effects of prior therapy. Pregnant or breast
        feeding. History of diabetes mellitus. Uncontrolled intercurrent illness. Congestive heart
        failure, unstable angina, or a myocardial infarction within 3 months of entering the study.

        HIV positive. Diagnosis of another malignancy may exclude subject from study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Changping Wu, M.D</last_name>
    <phone>8651968870978</phone>
    <email>wcpjjt@163.com</email>
  </overall_contact>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2015</study_first_submitted>
  <study_first_submitted_qc>July 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2015</study_first_posted>
  <last_update_submitted>July 8, 2015</last_update_submitted>
  <last_update_submitted_qc>July 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cytokine-Induced Killer Cells</keyword>
  <keyword>Milignant Gliomas</keyword>
  <keyword>Temozolomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

